These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 15482953)

  • 1. Synthesis, radiolabeling, and preliminary biological evaluation of [3H]-1-[(S)-N,O-bis-(isoquinolinesulfonyl)-N-methyl-tyrosyl]-4-(o-tolyl)-piperazine, a potent antagonist radioligand for the P2X7 receptor.
    Romagnoli R; Baraldi PG; Pavani MG; Tabrizi MA; Moorman AR; Di Virgilio F; Cattabriga E; Pancaldi C; Gessi S; Borea PA
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5709-12. PubMed ID: 15482953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor.
    Baraldi PG; del Carmen Nuñez M; Morelli A; Falzoni S; Di Virgilio F; Romagnoli R
    J Med Chem; 2003 Apr; 46(8):1318-29. PubMed ID: 12672232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decavanadate, a P2X receptor antagonist, and its use to study ligand interactions with P2X7 receptors.
    Michel AD; Xing M; Thompson KM; Jones CA; Humphrey PP
    Eur J Pharmacol; 2006 Mar; 534(1-3):19-29. PubMed ID: 16487507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [3H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X2/3 and P2X3 receptors.
    Jarvis MF; Bianchi B; Uchic JT; Cartmell J; Lee CH; Williams M; Faltynek C
    J Pharmacol Exp Ther; 2004 Jul; 310(1):407-16. PubMed ID: 15024037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and in vitro activity of N'-cyano-4-(2-phenylacetyl)-N-o-tolylpiperazine-1-carboximidamide P2X7 antagonists.
    Morytko MJ; Betschmann P; Woller K; Ericsson A; Chen H; Donnelly-Roberts DL; Namovic MT; Jarvis MF; Carroll WA; Rafferty P
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2093-6. PubMed ID: 18272365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonists.
    Betschmann P; Bettencourt B; Donnelly-Roberts D; Friedman M; George J; Hirst G; Josephsohn N; Konopacki D; Li B; Maull J; Morytko MJ; Moore NS; Namovic M; Rafferty P; Salmeron-Garcia JA; Tarcsa E; Wang L; Woller K
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3848-51. PubMed ID: 18595695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors.
    El-Tayeb A; Griessmeier KJ; Müller CE
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5450-2. PubMed ID: 16213725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
    Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
    Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synaptic terminals from mice midbrain exhibit functional P2X7 receptor.
    Marín-García P; Sánchez-Nogueiro J; Gómez-Villafuertes R; León D; Miras-Portugal MT
    Neuroscience; 2008 Jan; 151(2):361-73. PubMed ID: 18082965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20.
    Gessi S; Varani K; Merighi S; Cattabriga E; Pancaldi C; Szabadkai Y; Rizzuto R; Klotz KN; Leung E; Mac Lennan S; Baraldi PG; Borea PA
    Mol Pharmacol; 2005 Jun; 67(6):2137-47. PubMed ID: 15788741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the human P2X7 receptor by a novel protein tyrosine kinase antagonist.
    Shemon AN; Sluyter R; Stokes L; Manley PW; Wiley JS
    Biochem Biophys Res Commun; 2008 Jan; 365(3):515-20. PubMed ID: 17999916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.
    Keller M; Pop N; Hutzler C; Beck-Sickinger AG; Bernhardt G; Buschauer A
    J Med Chem; 2008 Dec; 51(24):8168-72. PubMed ID: 19053784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
    Dionisotti S; Ongini E; Zocchi C; Kull B; Arslan G; Fredholm BB
    Br J Pharmacol; 1997 Jun; 121(3):353-60. PubMed ID: 9179373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/-)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors.
    Zhang G; Huang N; Li YW; Qi X; Marshall AP; Yan XX; Hill G; Rominger C; Prakash SR; Bakthavatchalam R; Rominger DH; Gilligan PJ; Zaczek R
    J Pharmacol Exp Ther; 2003 Apr; 305(1):57-69. PubMed ID: 12649353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.
    Borrmann T; Hinz S; Bertarelli DC; Li W; Florin NC; Scheiff AB; Müller CE
    J Med Chem; 2009 Jul; 52(13):3994-4006. PubMed ID: 19569717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist.
    Jaime-Figueroa S; Greenhouse R; Padilla F; Dillon MP; Gever JR; Ford AP
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3292-5. PubMed ID: 15927468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
    Varani K; Merighi S; Gessi S; Klotz KN; Leung E; Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Borea PA
    Mol Pharmacol; 2000 May; 57(5):968-75. PubMed ID: 10779381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.